BioWorld

Jan. 29, 2004

Cytokinetics Files For IPO As Two Cancer Drugs Enter Clinic

With hopes of raising $86.25 million to advance two cancer drugs and a preclinical candidate for heart failure, Cytokinetics Inc. filed for its initial public offering. (BioWorld Today) Read More

Pozen Files Needed Rat Data For MT 100 NDA In Migraine

Original Carbon-14 Dating Limit Of 26,000 Years Reset At 50,000 Years To Be Future Evolutionary Yardstick

Genelabs Licenses Out Japanese Prestara Rights For Up To $12M

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...